PACB · Pacific Biosciences of California
Conviction · Low · more likely to lag the S&P 500 over the next three months
Wrong if: a daily close above $2.90
Note written ·
Price against the kill line
32.4% clear of its kill line on the 13 November 2026 close.
How to read this
This note expects the shares to lag the market, so its kill line sits above the price: a close above the red mark would prove the view wrong. Prices run from low on the left to high on the right. The dot is where the stock closed on 13 November 2026, left of the mark while it is below the line; a dot right of the mark has closed through it.
The scale is stretched near the line, so close calls are easy to see. More than 8% from the line, the stock reads well clear, with a hollow dot to show the figure is off the drawn scale.
The kill line is the research note's own test. The portfolio sells on business facts, not on a price. How the portfolio decides
Three months against the kill line
Daily closes, to . Red: the kill line, a daily close above $2.90, on record since 11 November 2026. The shares are up 62.0% since the close; the S&P 500 is down 2.1% over the same sessions. Figures in the note can cover a different window.
Kill line
A daily close above $2.90, above every close since the 4 November 2026 report, which would show the shares leading the S&P 500; or full-year 2026 revenue above $160M, the top of the narrowed guide.
Research onlyNot in the portfolio.
Catalyst
Key figures from the filings · Health Care
Quarter to 30 September 2026, filed 5 November 2026; valuation at the 13 November 2026 close
- Revenue, latest quarter ($M)
- 40.6
- Revenue, change on a year (%)
- +5.5
- Gross margin (%)
- 33.2
- Operating margin (%)
- −91.2
- Free cash flow, four quarters ($M)
- −143
- Net cash, cash less debt ($M)
- −444
- Enterprise value to sales (×)
- 6.5
- Free-cash-flow yield (%)
- −23.4
All filed numbers
What Pacific Biosciences of California reports to the SEC in its quarterly and annual filings. Each group states its period and filing date once; a figure dated otherwise says so. Built from the filings known on .
| Quarter to | Revenue ($M) | On a year (%) | Gross margin (%) | Operating margin (%) |
|---|---|---|---|---|
| first filed | 40.6 | +5.5 | 33.2 | −91.2 |
| first filed | 39.0 | −1.9 | 32.4 | −114.4 |
| first filed | 37.2 | +0.1 | 34.5 | −22.5 |
| first filed | 44.6 | +13.8 | 37.1 | −92.3 |
| first filed | 38.4 | −3.8 | 41.4 | −101.1 |
| first filed | 39.8 | +10.4 | 36.9 | −112.8 |
| Pre-tax income ($M) | −37.6 |
| Net income ($M) four quarters: −131 | −37.8 |
| Diluted shares, change on a year (%) against the quarter to 30 September 2025 | +3.5 |
| Operating cash flow ($M) | −137 |
| Capital spending ($M) | 6.4 |
| Free cash flow ($M) | −143 |
| Cash and short-term investments ($M) | 199 |
| Debt ($M) convertible debt | 643 |
| Net cash, cash less debt ($M) | −444 |
| Deferred revenue ($M) +5.5% on a year | 21.6 |
| Backlog, orders not yet delivered ($M) −10.1% on a year | 43.8 |
| Receivables ($M) | 38.3 |
| Inventory ($M) | 60.3 |
| Shareholders' equity ($M) | −61.4 |
| Market value ($M) | 613 |
| Enterprise value, market value plus net debt ($M) | 1,057 |
| Enterprise value to sales (×) | 6.5 |
| Enterprise value to operating income (×) | Not meaningful |
| Price to earnings (×) | Not meaningful |
| Price to book value (×) | Not meaningful |
| Free-cash-flow yield (%) | −23.4 |
Short interest (FINRA, settled 15 October 2026, published 26 October 2026): 15.0% of shares outstanding sold short, 2.2 days of average trading to cover, −0.6% since the previous report.
| Window | Bought | Sold |
|---|---|---|
| 90 daysfrom | $0 | $2.1M |
| 12 monthsfrom | $0 | $3.4M |
The thesis
Pacific Biosciences (PacBio) shares are more likely to lag the S&P 500 over the next three months. The third-quarter (Q3) 2026 report on 4 November 2026 showed modest revenue growth, a lower gross margin and a cut to the top of the full-year guide. Six days later the company set up a $100M at-the-market (ATM) stock sale program. The fourth-quarter report, expected in late February 2027, shows whether margin and consumable sales recover.
The rating is Low because the Q3 numbers did not match the three-month rally. Q3 revenue was $40.6M against $38.4M a year earlier, and generally accepted accounting principles (GAAP) gross margin fell to 33% from 41% (8-K Exhibit 99.1, 4 November 2026). The ATM agreement with Allen & Company, filed in an 8-K on 10 November 2026, gives the company a way to sell new shares into any rally.
At $2.09 on 11 November 2026, the shares still hold an 81.7% three-month gain. They trade between Barclays' $2 target and UBS's $2.70 target. The price already reflects October's partnership news. The Q3 report brought a narrower guide rather than faster revenue.
Bullish and bearish views on Pacific Biosciences of California, Inc.
The bull case on Pacific Biosciences of California, Inc. (PACB), in brief: revenue beat the consensus estimate. The bear case: gross margin fell eight points.
Bull case
- Revenue beat the consensus estimate. Q3 revenue of $40.564M beat the $40.386M consensus, and adjusted loss per share of $(0.11) beat the $(0.15) estimate, according to news reports of the 4 November 2026 results.
- Vega keeps adding new customers. PacBio placed 35 Vega benchtop systems in Q3 against 32 a year earlier. More than 90% went to new customers (8-K Exhibit 99.1, 4 November 2026).
- Restructuring is cutting costs. GAAP operating expenses fell to $50.5M from $54.8M a year earlier, which the company credits to lower personnel costs. Q3 included $3.0M of restructuring charges (8-K Exhibit 99.1, 4 November 2026).
- New chemistry is being adopted. More than half of Revio consumables revenue came from SPRQ-Nx chemistry in Q3. Two-thirds of the Revio installed base had upgraded software by quarter-end (8-K Exhibit 99.1, 4 November 2026).
- AI and population-genomics programs widen demand. PacBio announced a multi-year collaboration with Verily Health on 19 October 2026 and a TychoBio project covering more than 10,000 samples on 6 October 2026. Sampled won a Department of Veterans Affairs contract worth up to $27.1M on 28 September 2026 that runs on Revio systems.
- Two brokers raised targets after the report. Piper Sandler raised its target to $3 with a Neutral rating, and Barclays raised its target to $2 with an Underweight rating, both on 5 November 2026 (news headlines).
Bear case
- Gross margin fell eight points. GAAP gross margin was 33% in Q3 against 41% a year earlier. Non-GAAP gross margin was 36% against 42%. The company blamed higher memory costs and Vega manufacturing transition costs (8-K Exhibit 99.1, 4 November 2026).
- Consumables and pull-through slipped. Consumable revenue was $20.8M against $21.3M a year earlier. Annualized Revio pull-through per system fell to about $204,000 from about $236,000 (8-K Exhibit 99.1, 4 November 2026).
- The top of the guide was cut. PacBio narrowed full-year 2026 revenue guidance to $155–160M from $155–165M on 4 November 2026.
- Cash is shrinking against large debt. Cash, equivalents and investments were $199.4M on 30 September 2026, down from $279.5M on 31 December 2025. Convertible senior notes stood at $643.1M net, and stockholders' equity was a $61.4M deficit (8-K Exhibit 99.1, 4 November 2026).
- New share supply is now authorized. PacBio signed a $100M ATM sales agreement with Allen & Company on 10 November 2026, paying up to 3.0% of gross proceeds (8-K, 10 November 2026). The shares closed at $2.09 on 11 November 2026, the lowest close since the report.
- The finance chief left after selling stock. CFO Jim Gibson stepped down on 4 November 2026, and CEO Mark Van Oene became interim CFO (8-K, 4 November 2026). Gibson had exercised 500,000 options at $1.18 and sold 661,815 shares at $3.11 on 6 October 2026 under a Rule 10b5-1 plan (SEC Form 4, filed 8 October 2026).
- UBS cut its target. UBS lowered its target to $2.70 and kept a Neutral rating on 9 November 2026 (news headlines).
Price setup
The shares closed at $2.55 on 4 November 2026, before the report. They closed at $2.43 on 5 November 2026, the first session after it, and at $2.09 on 11 November 2026, the session after the ATM agreement was announced. All five closes since the report sit below the pre-report level.
The last close of $2.09 sits just above the 50-day moving average of $1.98. It is well above the 200-day moving average of $1.61 (both from adjusted daily closes as of 11 November 2026). The 52-week intraday high is $3.44, set on 6 October 2026, and the last close is 39.2% below it. The 52-week closing low is $1.11, set on 12 August 2026.
The 81.7% three-month gain is measured from the $1.15 close of 13 August 2026. The case turns on two levels. A close under the 50-day average would extend the post-report decline. A recovery through the $2.55 pre-report close would show buyers absorbing the new share supply.
Catalysts ahead
- 16 November 2026: PacBio presents at the Jefferies Global Healthcare Conference. This is the first management appearance after the ATM filing. Comments on ATM usage, cash runway and fourth-quarter gross margin show how much new share supply to expect.
- 18 November 2026: PacBio presents at the Stephens NASH26 Conference. Management can update on Vega demand and on converting the Verily and TychoBio programs into consumable revenue, which fell year over year in Q3.
- ~26 February 2027 (est.): Q4 and full-year 2026 results. Full-year revenue against the $155–160M guide, GAAP gross margin against Q3's 33%, year-end cash and any ATM sales show whether the business has caught up with the price.
What would change the view
A daily close above $2.90, above every close since the 4 November 2026 report, which would show the shares leading the S&P 500; or full-year 2026 revenue above $160M, the top of the narrowed guide.
What it trades with
PacBio trades with small-cap life-science tools and genomics names. Its largest moves have come on company announcements, broker actions and financing news. StockStory counted 87 single-session moves larger than 5% over the year to 5 October 2026. Illumina and Oxford Nanopore compete directly in long-read and methylation sequencing. PacBio sold its short-read assets to Illumina in February 2026 for $48.1M in net cash proceeds. Memory-chip prices now affect PacBio's gross margin, because the company cited higher memory costs in its Q3 2026 margin decline.
The evidence, claim by claim (8)
- Q3 2026 revenue was $40.6M vs. $38.4M in Q3 2025; instrument revenue $13.2M vs. $11.3M; consumable revenue $20.8M vs. $21.3M. PacBio Q3 2026 earnings release (8-K Exhibit 99.1) · as of
- Q3 2026 GAAP gross margin was 33% vs. 41% a year earlier; non-GAAP 36% vs. 42%, attributed to memory costs and Vega manufacturing transition costs. PacBio Q3 2026 earnings release (8-K Exhibit 99.1) · as of
- Cash, equivalents and investments were $199.4M on 30 September 2026 vs. $279.5M on 31 December 2025; convertible senior notes $643.1M net; stockholders' deficit $61.4M. PacBio Q3 2026 earnings release (8-K Exhibit 99.1) · as of
- Full-year 2026 revenue guidance was narrowed to $155–160M from $155–165M. PacBio Q3 2026 earnings release (8-K Exhibit 99.1) · as of
- Q3 2026 placements: 35 Vega systems vs. 32 (over 90% to new customers) and 15 Revio systems vs. 13; Revio annualized pull-through about $204,000 vs. $236,000. PacBio Q3 2026 earnings release (8-K Exhibit 99.1) · as of
- PacBio entered a sales agreement with Allen & Company for an at-the-market offering of up to $100M of common stock, with commission up to 3.0% of gross proceeds. PacBio Form 8-K and Form 424B5 prospectus supplement · as of
- CFO Jim Gibson stepped down; CEO Mark Van Oene was named interim CFO and Bill Meyer Chief Accounting Officer. PacBio Form 8-K · as of
- James Gibson II exercised 500,000 options at $1.18 and sold 661,815 shares at $3.11 on 6 October 2026 under a Rule 10b5-1 plan. SEC Form 4 filed 8 October 2026 · as of
Sources
- PACIFIC BIOSCIENCES OF CALIFORNIA, INC. - Form 8-K - FY2026 · sec.gov
- PACIFIC BIOSCIENCES OF CALIFORNIA, INC. - Form 8-K - FY2026 · sec.gov
- PACIFIC BIOSCIENCES OF CALIFORNIA, INC. - Form 424B5 - FY2026 · sec.gov
- Pacific Biosciences Enters Agreement for At-the-Market Stock Offering · tipranks.com
- PacBio Announces Third Quarter 2026 Financial Results · streetinsider.com
- Pacific Biosciences Q3 Revenue Grows 6% as Vega Transition Pressures Margins · panabee.com
Related · shared themes
AZTA
Azenta
Azenta is more likely to beat the S&P 500 over three months because its fiscal 2027 plan, issued 10 November 2026, adds 3% to 5% organic…
AVTR
Avantor
Avantor's lab-supply volumes are growing again, with Q3 2026 organic growth of 5.2% and a raised FY2026 outlook, but distribution margins…
CRL
Charles River Laboratories International
Charles River Laboratories' preclinical recovery passed its 4 November 2026 test with 4.7% organic growth, a 1.09 book-to-bill and raised…
EMBC
Embecta
Embecta Corp. shares are modestly favored to beat the S&P 500 as higher margins and debt repayment outweigh shrinking U.S. pen-needle…
See also · stocks to watch